Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot randomized trial of rectal faecal microbiota transplantation for alcohol use disorder with compensated alcohol-associated liver disease
ACTRN12626000765325Phase 2Not yet recruiting
- Sponsor
- St Vincent's Hospital Melbourne
- Start
- Jan 2027
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of biologically active human fecal material in alcohol use disorder (AUD) and alcoholic liver disease (ALD) (2 arms), sponsored by St Vincent's Hospital Melbourne. Primary endpoints: Feasibility of conducting the randomized pilot trial, Safety of a single rectal FMT enema compared with standard care and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
biologically active human fecal material
03
Conditions
alcohol use disorder (AUD)alcoholic liver disease (ALD)
Beyond the preview
Go deeper on ACTRN12626000765325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000765325.